Highly potent APIs - can your CMO handle them?
The importance of ensuring a facility has the right capabilities when selecting a CMO to handle high potency ingredients.
The growing market demand for high potency capabilities invariably means more companies are having to choose a reliable CMO partner. Easier said than done! Help, however, is at hand, as Manuel Leal, Business Development Director at Idifarma, shares his insight to help companies navigate their way through this potentially tricky course.
What should pharma companies consider when selecting a CMO for high potency production?
"Safety is a priority. The development and manufacturing of high potency products requires significant investment in high containment facilities, protective equipment and personnel training.
Introducing a new highly potent API into a manufacturing facility poses a risk that should always be handled with a thorough analysis of safety measures and cleaning levels. These issues should all be addressed and demonstrated by the CMO as part of the selection process.
At Idifarma, for instance, we can work with highly potent compounds up to level 4 OEB/OEL. We always conduct our own risk analysis for every new product - taking into account our facilities, equipment and personal protective equipment - to ensure we can handle it safely and without compromising quality."
High potency production obviously involves strict regulation too. What regulations should manufacturers follow within high potency facilities?
"The essential regulations are Good Manufacturing Practice (GMP), health and safety regulations for workers and environmental laws.
Recent updates to GMP determine a new approach to risk analysis based on toxicological assessments for shared or multi-product facilities, which covers most manufacturing sites. There are also changes related to prevention of cross contamination and supply chain traceability.
In addition, the European Medicines Agency (EMA) guidelines on setting health-based exposure limits should also be adhered to."
So, all manufacturers offering high potency facilities should in effect offer the same basic technical capabilities, quality and safety assurances. What other qualities should pharmaceutical companies be looking for in a CMO partner?
"Yes, there are minimum requirements, such as quality, technology and safety, which can be objectively assessed through HSE and quality audits. But then there are other aspects that should be checked when making a decision and these are usually harder to ascertain: client orientation and alignment, absence of conflicts of interest, reliability, flexibility and responsiveness. A track record of success and evidence of a long-term, company-wide commitment to HPAPI production are also equally important.
Price is also understandably a factor ,but prioritising this is often proven to be a risky strategy and not recommended."
What are the industry trends driving the need for more high potency capabilities?
"There is clearly growing market demand for high potency capabilities due to a number of factors. For example, there are an increasing number of ‘families’ of highly potent APIs for oncology treatments, such as the ‘nibs’ family of products (such as Sunitinib, Erlotinib and Sorafenib), being developed and marketed, which require specialised development and manufacturing facilities.
Increasing regulatory, safety and environmental requirements are also driving the need for specialist providers of high potency capabilities in the pharmaceutical industry."
In your opinion, what does the future hold for high potency facilities?
"Currently, approximately 25% of drugs in development worldwide are classified as highly potent. This number continues to rise, driven in particular by growth in the oncology market and cancer-related drugs, which account for approximately 60% of all highly potent APIs.
Because of this, I expect the demand for high potency CDMOs will grow steadily over the next 5-10 years, since the relevant investment needed for high potency facilities are capital intensive and are usually a deterrent for many clients to invest themselves. Instead, the outsourcing sector offers them readily available economical and efficient solutions.
Manuel Leal, is the Business Development Director at Idifarma. He is responsible for generating new business for the Spanish contract development and manufacturing organisation (CDMO) and exploring international markets as part of the company’s ongoing growth strategy."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance